Pharma Regulatory & IP Update 2026: FDA CGT Approvals, GLP-1 Wars, and EPO Case Law
Two minutes of quick reading Pharma Regulatory & IP Digest: 2026 CGT Trends, GLP-1 Breakthroughs, and EPO Patent Rulings This comprehensive digest analyses the critical updates impacting generic manufacturers, drug compounders, and IP strategists today. 1. The Competitive Generic Therapy (CGT) Market Race The traditional generic drug market is frequently characterised as a "race to the bottom," with heavy multi-competitor volume often triggering severe price erosions of 80% to 95% . To promote generic development in areas with historically inadequate competition, the FDA utilises the Competitive Generic Therapy (CGT) pathway under the FDA Reauthorisation Act (FDARA) . Securing a CGT designation offers a highly lucrative incentive: 180 days of market exclusivity . However, recent data highlights a stark commercial reality: securing a designation does not guarantee market exclusivity, and capturing the prize requires flawless operational timing . Exclusivity Granted vs...
